Screening for Methylated Poly(l-histidine) with Various Dimethylimidazolium/Methylimidazole/Imidazole Contents as DNA

Shoichiro Asayama1, Takao Kumagai2, Hiroyoshi Kawakami3

  • 1Department of Applied Chemistry, Tokyo Metropolitan University, 1-1 Minami-Osawa, Hachioji, Tokyo 192-0397, Japan. asayama-shoichiro@tmu.ac.jp.

Pharmaceutics
|August 27, 2015
PubMed

Insights

Methylated poly(l-histidine) (PLH-Me) was screened for efficient gene delivery. The PLH-Me(25)/DNA complex showed the highest gene expression in HepG2 cells, indicating a crucial balance of functional groups for DNA carrier design.

Area of Science:

  • Biomaterials Science
  • Gene Therapy
  • Polymer Chemistry

Background:

  • Methylated poly(l-histidine) (PLH-Me) is a novel polypeptide designed for gene delivery.
  • Controlling the ratio of dimethylimidazolium, methylimidazole, and imidazole groups is key to its function.

Purpose of the Study:

  • To screen PLH-Me variants with varying dimethylimidazolium group content (25%, 68%, 87%) as DNA carriers.
  • To evaluate the DNA binding stability and gene expression efficiency of these PLH-Me variants.

Main Methods:

  • Synthesized and characterized three PLH-Me variants: PLH-Me(25), PLH-Me(68), and PLH-Me(87).
  • Assessed DNA retention using competitive exchange with dextran sulfate.
  • Performed gene transfection experiments in HepG2 cells to measure gene expression.

Main Results:

  • PLH-Me(25) and PLH-Me(68) demonstrated comparable DNA retention to PLH-Me(87).
  • The PLH-Me(25)/DNA complex exhibited the highest gene expression levels in HepG2 cells.
  • The balance of dimethyl-imidazolium, methylimidazole, and imidazole groups significantly impacts DNA carrier performance.

Conclusions:

  • The specific ratio of functional groups in PLH-Me is critical for optimizing DNA carrier design.
  • PLH-Me(25) shows promise as an effective non-viral vector for gene delivery.
  • Further research into the structure-activity relationship of PLH-Me is warranted.

Related Concept Videos